Testing a new drug for advanced melanoma
Part of Cancer, Skin clinical trials.
This trial tests a new drug called OPM-101 combined with an immunotherapy (anti-PD-1) for people with advanced melanoma that has stopped responding to anti-PD-1 treatment. The goal is to see if the combination can overcome resistance and shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced melanoma (stage III or IV) that cannot be surgically removed or has spread.
- Your cancer has gotten worse while on a type of immunotherapy called anti-PD-1 (given alone or with certain other drugs).
- You have not had anti-PD-1 treatment in the last 4 weeks (or 6 weeks for some pembrolizumab schedules).
- You are willing to have a fresh tumor biopsy before starting and after 12 weeks of treatment (if in Phase 1b).
- You are 18 or older, in good enough health (ECOG score 0 or 1), and have adequate blood and organ function.
- You agree to use effective contraception during and for a period after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called LM103 for people with advanced melanoma who have already tried several standard treatments, including immunotherapy. The goal is to see if LM103 can help shrink tumors when other treatments have stopped working.
This trial tests a new drug (EIK1001) combined with the standard immunotherapy pembrolizumab (Keytruda) for people with advanced melanoma that cannot be removed by surgery or has spread. The goal is to see if adding EIK1001 is more effective than placebo plus pembrolizumab.
This trial tests a combination of three immunotherapy drugs (fianlimab, cemiplimab, and ipilimumab) for people with advanced melanoma that has stopped responding to previous PD-1/PD-L1 treatment. It aims to see if this new combination can help shrink or control the cancer.
This trial tests a combination of two drugs (iparomlimab and tuvonralimab) plus bevacizumab for people with advanced melanoma whose cancer got worse after prior immunotherapy. The goal is to see if this new combination can help when standard treatments stop working.
This trial tests a new immunotherapy drug (IMC-F106C) combined with standard treatments against the usual nivolumab-based therapy for people with advanced melanoma who have not been treated before. It's for people who carry a specific immune system marker (HLA-A*02:01) and are in fairly good health.
This trial compares a new drug, MB11, to the standard treatment Opdivo for people with advanced melanoma that hasn't been treated yet. The goal is to see if MB11 works just as well.
Hear when a new Advanced Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.